Welcome to our dedicated page for Yulong Eco-Matls news (Ticker: YECO), a resource for investors and traders seeking the latest updates and insights on Yulong Eco-Matls stock.
EV Biologics Corp (YECO) is a pioneering biotechnology company advancing stem cell-derived exosome therapeutics and nanoparticle-based biologics for regenerative medicine. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access verified information about YECO's biomanufacturing innovations, including Excyte subsidiary advancements and EcoCura™ product developments. Our curated news collection covers FDA filings, research collaborations, intellectual property updates, and biocompatible formulation breakthroughs – all essential for tracking progress in longevity therapeutics.
Bookmark this page for direct access to EV Biologics' official press releases, financial disclosures, and peer-reviewed research announcements. Stay informed about emerging applications of their nanotherapeutic platforms in age-related diseases and tissue regeneration through our comprehensive updates.
EV Biologics Corp (OTC PINK:YECO) has announced a groundbreaking funding agreement to raise between $25 million and $50 million through the world’s first Security Token Offering (STO) in the biotech sector. The STO, launching January 1, 2021, will finance research and development for Acute Lung Injury (ALI). Investors can purchase 100 million ALI tokens at $5 each, with the company retaining majority ownership. This innovative approach aims to increase YECO's value while avoiding share dilution. The company plans to pursue additional funding and up-listing opportunities in the future.
EV Biologics Corp (OTC PINK:YECO) announced it has completed all filings on OTC Markets, achieving a current reporting status within its target timeline. This development allows a broader range of brokers to trade its shares, enhancing trading accessibility. The company aims for Pink Current status following OTC Markets' review. CEO Daniel Mckinney highlighted efforts towards revolutionizing medicine through innovative biopharmaceuticals. The company is also focused on up-listing to OTCQB and enhancing its digital presence with a new website.
EV Biologics (formerly Yulong Eco-Materials Limited, OTC PINK:YECO) announced a collaboration with Vanderbilt University to leverage advanced instrumentation for extracellular vesicle (EV)-based diagnostics and therapeutics. This partnership aims to enhance QA/QC in developing biopharmaceuticals, with a focus on using nanoscale analytical methods. The company is investing in its analytical equipment and plans to obtain a new trading symbol with FINRA, aiming to become current in OTC filings by October end. YECO has 6.21 million shares outstanding, with a float of 1,016,375 shares.
Yulong Eco-Materials Limited (OTC PINK:YECO) announced plans to list its Securitized Token Offering (STO) on the CryptoSX digital exchange, a regulated platform for trading digital assets. The STO will fund the development of an extracellular vesicle drug targeting acute lung injury (ALI), which is linked to severe conditions like COVID-19. CEO Daniel McKinney highlighted this as a pioneering move in biotech funding through licensed exchanges. The company aims to minimize shareholder dilution by not issuing new shares and seeks to up-list to OTCQB.
Yulong Eco-Materials Limited / EV Biologics, Inc. (OTC:YECO) has announced a groundbreaking initiative to issue a Securitized Token Offering (STO), aiming to finance the development of a novel biological drug targeting acute lung injury (ALI). This first-of-its-kind offering will utilize a SEC registered security on an Ethereum-based blockchain, granting token holders ownership of intellectual property and a share in future revenues. CEO Daniel Mckinney emphasized the potential impact on drug development financing, with plans to retain majority ownership to minimize shareholder dilution.
Yulong Eco-Materials Limited (YECO) has announced plans to establish an incubator laboratory in Nashville, TN, dedicated to developing cell and extracellular vesicle-based therapeutics. The lab, located near Vanderbilt University, will enhance biological properties of mesenchymal stem cells (MSCs) and produce disease-specific extracellular vesicles for FDA approval in treating conditions like COVID-19 and autoimmune diseases. The company aims to minimize shareholder dilution through a new funding model. Additionally, a name change to EV Biologics is underway, with a new trading symbol expected soon.
Yulong Eco-Materials Limited (OTC PINK:YECO) announced plans to develop an incubator laboratory for cell and extracellular vesicle (EV) based therapeutics. The modern lab will focus on bioengineered cell lines, particularly mesenchymal stem cells (MSCs), to create clinical therapeutics targeting various conditions, including acute lung injury and autoimmune diseases. CEO Daniel Mckinney highlighted a unique funding model aimed at minimizing shareholder dilution. Additionally, the company is negotiating acquisitions with U.S. stem cell firms and plans to change its name and trading symbol.
Yulong Eco-Materials Limited (OTC PINK:YECO) announced the appointment of Dr. Jason Sanders as Chief Medical Officer. Dr. Sanders, an expert in extracellular vesicle science and regenerative medicine, aims to advance research on exosome-based diagnostics and therapeutics. CEO Daniel McKinney emphasized Dr. Sanders' expertise as pivotal for the company's R&D. The company is negotiating to acquire a leading U.S. stem cell firm. YECO has 6.21 million shares issued, with a float of 1,016,375 shares, signaling potential investment interest.
